From MarketBeat:



Arkadios Wealth Advisors increased its position in Johnson & Johnson by 54.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. Several other institutional investors have also increased their holdings in the company. Analysts have issued a variety of ratings on JNJ shares, with a consensus rating of “Moderate Buy” and an average target price of $168.75. NYSE JNJ opened at $155.46 with a 12 month low of $144.95 and high of $180.93.

Johnson & Johnson reported a quarterly earnings of $2.66 EPS and had a net margin of 36.32% along with a return on equity of 37.14%. The company recently announced a quarterly dividend and offers a variety of products in the healthcare field. Finally, while Johnson & Johnson currently has a “Hold” rating among analysts, top-rated analysts believe that there are five stocks that are better buys.

MarketBeat has released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued.



Read more: Johnson & Johnson (NYSE:JNJ) Shares Acquired by Arkadios Wealth Advisors